PMID- 31942192
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 11
IP  - 3
DP  - 2020
TI  - Efficacy of EGFR-TKIs with or without angiogenesis inhibitors in advanced 
      non-small-cell lung cancer: A systematic review and meta-analysis.
PG  - 686-695
LID - 10.7150/jca.34957 [doi]
AB  - In the present study, we evaluated the efficacy and safety of epidermal growth 
      factor receptor tyrosine kinases (EGFR-TKIs) combined with or without 
      angiogenesis inhibitors in advanced non-small-cell lung cancer (NSCLC). We 
      searched published randomized controlled trials (RCTs) comparing EGFR-TKIs with 
      and without angiogenesis inhibitors for the treatment of advanced NSCLC. PubMed, 
      EMBASE, PMC, the American Society of Clinical Oncology (ASCO) and the European 
      Society of Medical Oncology (ESMO) databases were searched. The extracted data on 
      progression-free survival (PFS) and overall survival (OS) were measured in terms 
      of hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). In 
      addition, odds ratios (ORs) and corresponding 95% CIs were pooled for objective 
      response rate (ORR) and disease control rate (DCR). Risk ratios (RRs) and 
      corresponding 95% CIs were pooled for risk of adverse events (AEs). EGFR-TKIs 
      combined with angiogenesis inhibitors showed significant improvements in PFS (HR 
      0.72, 95% CI 0.61-0.84, P <0.0001), ORR (OR 1.51, 95% CI 1.17-1.97, P=0.002) and 
      DCR (OR 1.49, 95% CI 1.24-1.81, P<0.0001) compared with EGFR-TKIs combined with 
      placebo. However, EGFR-TKIs combined with angiogenesis inhibitors failed to 
      improve OS (HR 0.94, 95% CI 0.84-1.05, P = 0.26). In addition, diarrhea, 
      hypertension, thrombocytopenia, neutropenia, fatigue, rash, and dermatitis 
      acneiform were significantly increased in patients treated with angiogenesis 
      inhibitors. Thus, EGFR-TKIs combined with angiogenesis inhibitors were superior 
      to EGFR-TKIs alone in advanced NSCLC due to their effects on PFS, ORR and DCR, 
      but the increased incidence of AEs had an influence on the tolerability of this 
      combination therapy.
CI  - (c) The author(s).
FAU - Chen, Zhaoxin
AU  - Chen Z
AD  - Cancer Center, Beijing Friendship Hospital, Capital Medical University, No. 95 
      Yong An Road, Xi Cheng District, Beijing, 100050, China.
FAU - Wei, Jia
AU  - Wei J
AD  - Cancer Center, Beijing Friendship Hospital, Capital Medical University, No. 95 
      Yong An Road, Xi Cheng District, Beijing, 100050, China.
FAU - Ma, Xiaoting
AU  - Ma X
AD  - Cancer Center, Beijing Friendship Hospital, Capital Medical University, No. 95 
      Yong An Road, Xi Cheng District, Beijing, 100050, China.
FAU - Yu, Jing
AU  - Yu J
AD  - Cancer Center, Beijing Friendship Hospital, Capital Medical University, No. 95 
      Yong An Road, Xi Cheng District, Beijing, 100050, China.
LA  - eng
PT  - Journal Article
DEP - 20200101
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC6959046
OTO - NOTNLM
OT  - EGFR-TKI
OT  - NSCLC
OT  - angiogenesis
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2020/01/17 06:00
MHDA- 2020/01/17 06:01
PMCR- 2020/01/01
CRDT- 2020/01/17 06:00
PHST- 2019/03/17 00:00 [received]
PHST- 2019/10/21 00:00 [accepted]
PHST- 2020/01/17 06:00 [entrez]
PHST- 2020/01/17 06:00 [pubmed]
PHST- 2020/01/17 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - jcav11p0686 [pii]
AID - 10.7150/jca.34957 [doi]
PST - epublish
SO  - J Cancer. 2020 Jan 1;11(3):686-695. doi: 10.7150/jca.34957. eCollection 2020.